Meeting NewsVideo

VIDEO: ASCEND trial offers 'mixed messages' on aspirin, omega-3

MUNICH — In this video exclusive, Jeffrey T. Kuvin, MD, FACC, provides his perspective on the ASCEND trial of aspirin and omega-3 fatty acids for primary CVD prevention in patients with diabetes.

While the trial offers valuable information, it yields “mixed messages,” Kuvin, chief of the section of cardiovascular medicine at the Heart and Vascular Center at Dartmouth-Hitchcock Medical Center and professor of medicine at Dartmouth College Geisel School of Medicine, told Cardiology Today.

In the ASCEND population, aspirin reduced vascular events but increased bleeding, while a dose of 1 g per day of omega-3 fatty acids did not reduce vascular events.

Watch the video for more.

MUNICH — In this video exclusive, Jeffrey T. Kuvin, MD, FACC, provides his perspective on the ASCEND trial of aspirin and omega-3 fatty acids for primary CVD prevention in patients with diabetes.

While the trial offers valuable information, it yields “mixed messages,” Kuvin, chief of the section of cardiovascular medicine at the Heart and Vascular Center at Dartmouth-Hitchcock Medical Center and professor of medicine at Dartmouth College Geisel School of Medicine, told Cardiology Today.

In the ASCEND population, aspirin reduced vascular events but increased bleeding, while a dose of 1 g per day of omega-3 fatty acids did not reduce vascular events.

Watch the video for more.

    See more from European Society of Cardiology Congress